How To Label Rx Drugs for Abuse And Dependence: US FDA Gives Directions For Consistency
Labeling should include signs and symptoms of withdrawal as well as abuse-deterrent properties, draft guidance states.
You may also be interested in...
Draft guidance says US FDA will consider product's benefit-risk balance relative to approved analgesics; it is particularly interested in comparative efficacy and safety data.
Advisory committee members are divided on whether agency should restrict access to higher dose opioids, but most want option kept on the table.
Pharma industry critics herald the agreement for allowing many manufacturers around the world to make the COVID-19 therapeutic and for its transparency. If Merck can do it, they ask, why can’t other companies?